Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 12/20 | 0.57 |
| ▸ | ACACB | O00763 | 5/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | FABP1 | P07148 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834562 | 0.86 | ACACA (0.56) | ACACAACACBPARP10PARP15PARP2 | |
| SCHEMBL19405880 | 0.85 | ACACA (0.65) | ACACAACACBMAPTPARP10PARP15 | |
| SCHEMBL19834467 | 0.83 | ACACA (0.60) | ACACAACACBPARP10PARP15PARP2 | |
| SCHEMBL15613593 | 0.82 | L3MBTL1 (0.67) | ACACAACACBTDP1L3MBTL1MEN1 | |
| SCHEMBL19405726 | 0.82 | PARP10 (0.71) | ACACAACACBKMT2APARP10PARP15 | |
| SCHEMBL19405817 | 0.82 | ACACA (0.65) | ACACAACACBMEN1MAPTKMT2A | |
| SCHEMBL931524 | 0.81 | HPGD (0.52) | TDP1L3MBTL1PARP10PARP15NR1H4 | |
| SCHEMBL19834496 | 0.80 | ACACA (0.48) | ACACAACACBMEN1MAPTKMT2A | |
| SCHEMBL15474259 | 0.80 | ACACA (0.58) | ACACAACACBTDP1L3MBTL1 | |
| SCHEMBL931179 | 0.80 | HPGD (0.54) | TDP1L3MBTL1PARP10PARP15NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| EP-3225618-B1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002322-A1 | BICYCLIC COMPOUND | ACACA, ACACB, ACAT1 | ACACA 1/4885ACACB 2/4885TDP1 4465/4885 |
| US-10301292-B2 | Bicyclic compound | ACACA, ACACB, ACAT1 | ACACA 1/4885ACACB 2/4885TDP1 4465/4885 |
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885TDP1 4753/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885TDP1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.